The BIOvector provides high signal amplitudes; the fractal coating increases the sensing surface area, and the unique lossless compression algorithm enhances the clarity of the signals.

• It is comfortable, discreet, suits different body forms, and MRI scanning can be performed without any waiting period after injection, as the device is 1.5 T and 3.0 T full-body MR conditional. So it is both patient and diagnostically friendly, and makes the whole process of cardiac monitoring simpler and more efficient.

BIOMONITOR III’s combination of our BIOvector design, the fractal coating on its sensing surface area, and a smart lossless compression algorithm deliver high amplitude signal quality.

• Higher signal quality reduces the impact of noise and artifact, reduces ambiguity in analysis, and improves the efficiency of provider diagnosis.
• Clear P-wave and R-wave visibility supports faster, more confident ECG evaluation.
• Low noise also contributes to ECG clarity, which in turn, can lead to easier and quicker rhythm classification.

Intelligent Memory Management ensures that the detection of both overlapping arrhythmia episodes and patient triggered episodes are stored, with corresponding ECGs always available for evaluation.

• Overwriting older, more relevant episodes with newer, less relevant data makes classification more difficult. Intelligent Memory Management minimizes this risk, by retaining the most clinically valid episodes.
• When an AF episode is ongoing during transmission, the monitor transmits both its onset episode and duration.

Home Monitoring achieves industry-leading transmission success rates, along with high levels of patient adherence and satisfaction.

• The system works via a smartphone-sized CardioMessenger^Smart mobile unit. It is simple to use, and requires no patient interaction for successful daily data transmissions.
• The unit is battery operated making it easy for patients while travelling, with a battery life of 48 hours.
• BIOMONITOR III can transmit up to six ECGs to Home Monitoring each day, increasing physicians’ opportunity to evaluate patient status remotely.
• Daily verification of data transmissions contributes to an industry leading transmission success rate of 95%².
• Home Monitoring achieves 90%³ patient adherence, 99%⁴ of patients find it easy to use, and patient satisfaction stands at 98%⁴.
• BIOMONITOR III has a longevity of 4 years. It is also 1.5T and 3.0T full-body MR conditional and there is no waiting period after the injection procedure.
• Additional inputs can be provided with BIOTRONIK’s patient app, which has a symptom diary that via direct contact or our Home Monitoring Service Center, keeps patient and physicians fully informed.